In psoriasis patients, the neutralization of IL-17A by ixekizumab [168] or secukinumab [69] significantly decreases histological acanthosis, the number of Ki-67+-proliferating keratinocytes, and epidermal cytokeratin 16 expression. Here, KRT16 is linked to psoriasis.